Anti-tuberculosis Drugs Market Outlook 2026-2034: by Route of Administration (Oral, Injectable), Drug Class, End User, Distribution Channel

The Anti-tuberculosis Drugs Market is estimated at US$1.5 billion in 2026 and is projected to grow at a CAGR of 5.2% to reach US$2.3 billion by 2034.

Market Overview

The anti-tuberculosis drugs market includes drug therapies used to treat active and latent tuberculosis across public health systems, hospitals, and infectious disease care programs. The value chain spans active ingredient sourcing, formulation, donor and government procurement, public health distribution, hospital dispensing, and treatment adherence support.

Major end uses include drug-sensitive tuberculosis treatment, resistant tuberculosis management, preventive therapy, and community health intervention programs. At the same time, the market faces challenges linked to drug resistance, patient adherence, funding dependence, and access gaps in vulnerable populations.

Market Segmentation

By Route of Administration

• Oral
• Injectable

By Drug Class

• Isoniazid
• Rifampin
• Ethambutol
• Pyrazinamide
• Fluoroquinolones
• Bedaquiline
• Pretomanid
• Delamanid
• Aminoglycosides
• Thioamides
• Cyclic Peptides
• Other Drug Classes

By End User

• Hospitals & Clinics
• Non-Profit Organizations
• Private Diagnostic Centers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others (NGO & Donation Channels, Public Procurement & DOTS Programs)

Key Companies Analysed

• Johnson & Johnson
• Otsuka Pharmaceutical
• Lupin
• Mylan
• Sun Pharmaceutical
• MacLeods Pharmaceuticals
• Cipla
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
• Hikma Pharmaceuticals
• Sandoz
• Sanofi
• Bayer
• Eli Lilly
• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Torrent Pharmaceuticals
• Viatris
• FDC Limited

Geographic Coverage

• North America - Market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Sweden
  • Russia
  
  
• Asia-Pacific - Market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru
  
  

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

• Updated PDF report and an MS Excel workbook containing market tables and figures.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data.
• Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.